Accéder au contenu
Merck

Novel LAMP2 mutations in Chinese patients with Danon disease cause varying degrees of clinical severity.

Clinical neuropathology (2014-04-03)
Su-shan Luo, Jian-ying Xi, Shuang Cai, Chong-bo Zhao, Jia-hong Lu, Wen-hua Zhu, Jie Lin, Kai Qiao, Yin Wang, Zhu-rong Ye
RÉSUMÉ

Danon disease is an Xlinked dominant lysosomal glycogen storage disorder characterized by cardiomyopathy, skeletal myopathy, and mental retardation. This study described two Chinese cases of Danon disease in order to broaden the phenotypic and genetic spectrum. Clinical data were collected and LAMP2 mutations were analyzed. Patient A had fluctuating limb weakness during 6 months follow-up and was diagnosed with drug-induced myopathy due to anti-hepatitis B therapy with lamivudine. However, the first muscle biopsy with large cytoplasmic vacuoles confused the diagnosis and led to the second biopsy that allowed for the final diagnosis. Patient B had severe cardiac disturbances leading to sudden death. Molecularly, patient A harbored a synonymous mutation adjacent to the exon 6-intron 6 junction; mRNA analysis provided evidence that totally abolished the donor site and caused skipping of exon 6. Patient B harbored a frame-shift deletion mutation in exon 3 (c.396delA) leading to a truncated protein. To our knowledge, this is the first report of Danon disease caused by a synonymous exon mutation that affected mRNA splicing, which indicates that a synonymous substitution may not be silent when it is in the exon sequences close to the splice sites. It is also the first description of Danon disease clinically presenting as druginduced myopathy at onset; the pathological changes might be the key point for making a differential diagnosis. *These two authors contributed equally to this work.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-LAMP2 antibody produced in rabbit